EAS 2026丨三大Late Breaker专场重磅来袭，前沿研究不容错过！
时间：2026-05-05 17:35:37 热度：37.1℃ 作者：网络
2026年5月24-27日，第94届欧洲动脉粥样硬化学会年会（EAS 2026）将在希腊雅典盛大举办，其中Late Breaker专场再度成为最大看点之一。本次大会共设置三大Late Breaker专场，涵盖PCSK9新型治疗策略、临床干预新证据以及基础研究最新进展，集中呈现当前最具潜力的前沿成果，包括基因编辑、口服PCSK9抑制剂、炎症通路干预及ANGPTL3等新靶点探索等热点方向。随着大会日程正式公布，POCKETIN特别整理了值得重点关注的Late Breaker内容，带你提前锁定本届大会的核心亮点。
Late Breaker Abstracts in PCSK9 pharmacology
北京时间：05-25 20:45~22:15
IN VIVO BASE EDITING OF PCSK9 WITH VERVE-102 ENABLES POTENT AND DURABLE LDL-C REDUCTION IN PATIENTS WITH HYPERCHOLESTEROLEMIA
使用VERVE-102对PCSK9进行体内碱基编辑，可在高胆固醇血症患者中实现强效且持久的LDL-C降低
Scott B. Vafai (United States of America)
EFFECT OF ENLICITIDE, AN ORAL PCSK9 INHIBITOR, ON APOLIPOPROTEIN-B (APOB) IN PHASE 3 TRIALS
口服PCSK9抑制剂Enlicitide在3期试验中对载脂蛋白B的影响
Alberico L. Catapano (Italy)
EPIGENETIC PCSK9 SILENCING WITH STX-1150 PROVIDES DURABLE LDL-C CONTROL AFTER A SINGLE DOSE
使用STX-1150进行表观遗传PCSK9沉默，单次给药后提供持久的LDL-C控制
Benjamin Oakes (United States of America)
LIPOPROTEIN(A) LEVELS, RISK OF CARDIOVASCULAR EVENTS AND BENEFIT OF EVOLOCUMAB: FINDINGS FROM THE VESALIUS-CV TRIAL.
脂蛋白(a)水平、心血管事件风险及依洛尤单抗的获益：来自VESALIUS-CV试验的研究结果
Victorien Monguillon (United States of America)
EFFICACY AND SAFETY OF LERODALCIBEP, A NOVEL THIRD GENERATION PCSK9 INHIBITOR, IN SUBJECTS WITH SEVERE LDL-C ELEVATIONS COMPLETING THE 124-WEEK OPEN-LABEL PHASE 3 EXTENSION STUDY
新型第三代PCSK9抑制剂Lerodalcibep在完成124周开放标签3期扩展研究的重度LDL-C升高受试者中的有效性与安全性
David Kallend (United States of America)
Late Breaker Clinical Abstracts
北京时间：05-26 20:45~22:15
ORAL NLRP3 INHIBITOR RUVONOFLAST PROVIDES RAPID, ROBUST AND REVERSIBLE INFLAMMATION REDUCTION IN PEOPLE WITH RESIDUAL INFLAMMATORY RISK OF ASCVD
口服NLRP3抑制剂Ruvonoflast在具有ASCVD残余炎症风险的人群中提供快速、强效且可逆的炎症降低
Kausik K. Ray (United Kingdom)
MECHANISM OF ANGPTL3/8 INHIBITION BY APOA5 AND THERAPEUTIC IMPLICATIONS
APOA5抑制ANGPTL3/8的机制及其治疗意义
Anni Kumari (Denmark)
OLEZARSEN FOR ACUTE PANCREATITIS RISK IN PATIENTS WITH TRIGLYCERIDES >10 MMOL/L
Olezarsen用于甘油三酯>10 mmol/L患者的急性胰腺炎风险
Andre Zimerman (Brazil)
LIVER-TARGETED ANGPTL3 SILENCING WITH AZD1705 LOWERS ATHEROGENIC LIPOPROTEINS: PRECLINICAL VALIDATION AND PHASE 1 RESULTS
肝脏靶向ANGPTL3沉默药物AZD1705降低致动脉粥样硬化脂蛋白：临床前验证及1期结果
Niklas Bergh (Sweden)
COMPARABLE LDL-C REDUCTIONS WITH BEMPEDOIC ACID USED ALONE OR WITH BACKGROUND STATIN AND/OR EZETIMIBE THERAPY: REAL WORLD EVIDENCE FROM THE MILOS STUDY
贝派地酸单用或联合背景他汀和/或依折麦布治疗均可实现相当的LDL-C降低：来自MILOS研究的真实世界证据
Thomas Vanassche (Belgium)
PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF PLOZASIRAN IN SUBJECTS WITH RENAL OR HEPATIC IMPAIRMENT
Plazasiran在肾功能或肝功能不全受试者中的药代动力学、药效学及安全性
Jennifer Hellawell (United States of America)
Late Breaker Basic Science Abstracts
北京时间：05-27 15:30~17:00
PERIVASCULAR FAT IMAGING BIOMARKERS OF VASCULAR INFLAMMATION AS PROGNOSTIC ENDPOINTS IN EARLY PHASE CLINICAL TRIALS AND PRECISION MEDICINE: INSIGHTS FROM THERAPEUTIC TARGETING OF LOX1
血管炎症的血管周围脂肪成像生物标志物作为早期临床试验和精准医疗中的预后终点：来自靶向LOX1治疗的见解
Charalambos Antoniades (United Kingdom)
TRANSCRIPTOMIC, SPECIFIC MARKER, AND PATHWAY ANALYSIS OF SMOOTH MUSCLE CELL FOAM CELLS IN HUMAN ATHEROSCLEROSIS
人动脉粥样硬化中平滑肌细胞泡沫细胞的转录组学、特异性标志物及通路分析
Sima Allahverdian (Canada)
PROTEOMIC AND KINETIC ANALYSIS OF INTACT LIPOPROTEIN(A) PARTICLES DEMONSTRATES SLOW APO(A) CLEARANCE AND EXTRACELLULAR VESICLE ASSOCIATION.
完整脂蛋白(a)颗粒的蛋白质组学及动力学分析表明其具有缓慢的载脂蛋白(a)清除及细胞外囊泡结合特性
Gissette Reyes-Soffer (United States of America)
IMPACT OF CLONAL HEMATOPOIESIS ON LONG-TERM MORTALITY ACROSS THE SPECTRUM OF CORONARY ARTERY DISEASE
克隆性造血对冠状动脉疾病谱长期死亡率的影响
Roland J?ger (Austria)
STRESS SUSCEPTIBILITY DRIVES MYELOPOIESIS TO IMPAIR ATHEROSCLEROSIS RESOLUTION
应激易感性驱动髓系造血从而损害动脉粥样硬化的消退
Ozlem Tufanli (United States of America)
INTRODUCTION OF A PREMATURE STOP CODON IN APOLIPOPROTEIN B GENE RESHAPES LOW-DENSITY LIPOPROTEINS AND RESULTS IN REDUCTION OF CHOLESTEROL IN HYPERCHOLESTEROLEMIC MICE
在载脂蛋白B基因中引入提前终止密码子重塑低密度脂蛋白并导致高胆固醇血症小鼠胆固醇降低
Cesare Canepari (Italy)
